Investors & News

Investor Relations

Ascendis Pharma is a clinical stage biopharmaceutical company applying its TransCon technology to develop a pipeline of long-acting prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.

Stock Information
ASND (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 3.15 (4.71%)
Data as of 03/16/18 4:00 p.m. ET
Refresh quote
Stock chart for: ASND.O.  Currently trading at $63.80 with a 52 week high of $69.00 and a 52 week low of $21.95.
Recent NewsMore >>
Ascendis Pharma A/S Announces Year-End 2017 Financial Results and Business Update Conference Call on March 28
Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs
Ascendis Pharma A/S Announces Proposed Public Offering of ADSs
Upcoming EventsMore >>
There are currently no events scheduled.
Primary IR Contact
Scott T. Smith
Chief Financial Officer
Ascendis Pharma

Data provided by Nasdaq. Minimum 15 minutes delayed.